$LIVE to Unveil Plans for Significant Enhancements to

New Post Public Reply Private Reply Replies (1) Message Board
PYCKtradr PYCKtradr #34511
$LIVE to Unveil Plans for Significant Enhancements to livedeal.com on March 12 in Light of Excess Demand and User Feedback

LAS VEGAS--(BUSINESS WIRE)--February 25, 2014--
LiveDeal Inc. (NASDAQ: LIVE) ("LiveDeal" or the "Company") is a publicly traded company that operates livedeal.com, an innovative platform using geo-location to enable restaurants to communicate and publish real-time and instant offers to nearby consumers. Due to excessive demand and enthusiastic feedback from consumers and restaurants, the Company today announced that it will unveil plans for enhancements in a forthcoming version of its successful mobile marketing deal platform on March 12, 2014.

www.LiveDeal.com - real-time mobile restaurant marketing platform for restaurants. (Photo: Business Wire)

Leveraging its experience in the curation of thousands of deals in four major US cities, LiveDeal is poised to release a version of the "real-time" deal platform with further enhanced features and functionality that will enable restaurants in cities throughout the US and internationally to adopt the platform with ease, thus laying the groundwork for exponential growth.

Jon Isaac, President and CEO of LiveDeal, said, "Through careful analysis of both consumer and restaurant feedback and usage habits we feel that we have molded the LiveDeal platform into a more robust experience." He continued, "Furthermore, to meet the growing demand for a better restaurant deal platform very soon we plan to make it possible for international expansion whereby LiveDeal can be adopted in any city in the world."

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring Advances in AI and Digital R&D Innovation by ICON plc

Updated Category News Views 227

Recent Developments in AI and Digital Innovation by ICON plc ICON plc, a globally recognized clinical research organization (NASDAQ: ICLR), has recently conducted an extensive survey exploring the integration of Artificial Intelligence (AI) and digital tools within clinical research. Engaging with over 100 professionals in the biotech and pharmaceutical industries across...

Continue Reading
Tesla's Self-Driving Claims Under Fire: Industry Reactions

Updated Category News Views 167

Tesla's License Suspension in California Recently, a court in California announced a significant development affecting Tesla Inc. (NASDAQ: TSLA). The court decided to suspend Tesla's license to sell vehicles for 30 days due to a lawsuit concerning misleading claims about the company's Full Self-Driving (FSD) technology. If Tesla does not adapt its policies within 90 days,...

Continue Reading
Sunnova Energy Faces Challenges Amid Revenue Declines in 2024

Updated Category News Views 384

Sunnova Energy Experiences Financial Struggles Sunnova Energy International Inc. (NOVA) has encountered a challenging period, with its shares trading lower in the premarket on Monday following a disappointing report detailing its fourth quarter and full-year financial results. The financial landscape for Sunnova shows a revenue of $224.127 million, which unfortunately...

Continue Reading
Kerusso's Important Contributions in Faith and Community Work

Updated Category News Views 133

Kerusso's Inspiring Charitable Contributions in 2025 Kerusso Activewear, a prominent Christian apparel and gift brand, has ended the year with a remarkable achievement of over $400,000 in charitable contributions. This reflects their steadfast commitment to enriching lives through faith-based approaches and generous support for individuals in need. Growing Demand for...

Continue Reading
Prelude Therapeutics and Incyte Join Forces for JAK2JH2 Inhibitor

Updated Category News Views 101

Prelude Therapeutics Partners with Incyte on JAK2V617F Program Incyte establishes exclusive option to acquire Prelude’s innovative programs These inhibitors have the potential to modify disease outcomes in patients with myeloproliferative neoplasms (MPNs) Prelude Therapeutics, a clinical-stage oncology company, has recently made headlines with an exciting announcement...

Continue Reading